Cannabinoids in traumatic brain injury: preclinical and clinical research

Introduction and clinical context

The study Cannabinoids in traumatic brain injury: preclinical and clinical research (PMC · 2023) is part of the scientific research on the use of cannabinoids in traumatic brain injury.

In traumatic brain injury (TBI), interest in cannabinoids stems from their anti-inflammatory and potentially neuroprotective properties, observed mainly in preclinical research. Clinical studies investigate outcomes associated with cannabis use after the trauma. The evidence is still early and there is no consolidated indication; it is a research frontier in neuroscience.

Understanding what science shows about the use of cannabinoids in traumatic brain injury helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Review of the anti-inflammatory and neuroprotective effects of cannabinoids in traumatic brain injury. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

In traumatic brain injury, the interest stems from the neuroprotective and anti-inflammatory role of the endocannabinoid system, activated after the injury to limit excitotoxicity and oxidative stress; CBD and THC are studied for these effects, especially in preclinical models. The clinical evidence is still early and there is no consolidated indication. In terms of safety, the sedative and cognitive effects require caution precisely in patients with brain injury. Any use should be assessed individually, in the context of neurological rehabilitation.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PMC · 2023). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis help after a head injury?

The research is early (anti-inflammatory/neuroprotective effects under study); there is no consolidated indication.

Where does the evidence come from?

Mainly from preclinical research and exploratory clinical studies.